← All trials
NCT05468203
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 29, 2023
- Primary completion
- Aug 31, 2026
- Completion date
- Mar 1, 2027
- First posted
- Jul 21, 2022
- Last posted
- Dec 1, 2023
- Enrollment
- 3000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of New South WalesLead sponsor
- University of GroningenCollaborator
- University of New South WalesStudy director
- Australian and New Zealand Intensive Care Society Clinical Trials GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.